Silence Theraputics and Mallinckrodt have entered a collaboration to develop and commercialize RNAi drug targets designed to inhibit or ‘silence’ the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation.   The agreement provides Mallinckrodt with an exclusive worldwide license for C3 (SLN500) – a preclinical asset that targets a specific protein in the complement pathway – and an option for up to two ...